5th Oligonucleotides for CNS Summit

Memo

With clinical momentum from Eli Lilly's lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals' ALN-APP siRNA, Wave's Phase 1b/2a positive SELECT-HD data, 170+ biotech and 30+ pharma active in the field, and a surge of novel approaches, the oligonucleotide field shows no signs of slowing down. The 5th Oligonucleotides for CNS Summit unites a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs. This August, hear from Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to redefine the landscape of oligonucleotide research. URLs:Tickets: https://go.evvnt.com/3040862-2?pid=5569Brochure: https://go.evvnt.com/3040862-3?pid=5569 Date and Time: Wednesday, 27 August 2025 at 08:30 to Friday, 29 August 2025 at 16:05 Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Discovery Prices:Drug Developer Pricing - Conference + Workshop Day: USD 3497.00,Drug Developer Pricing - Conference Only: USD 2599.00,Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,Solution Provider Pricing - Conference Only: USD 3699.00 Speakers: Alice Stanton, Postdoctoral Fellow, Massachusetts Institute of Technology, Bruce Morimoto, Vice President, Drug Development, Principal Consultant, Deepak Sampath, Senior Vice President, Head of Research, Ultragenyx Pharmaceuticals, Fay Touti, Director, Oligonucleotide and Conjugation Chemistry, Apellis Pharmaceuticals, Gerard Platenburg, Chief Scientific Officer, ProQR, Hélène Tran, Director of Oligotherapeutics Program, Servier, Hideaki Tomita, Group Leader (Biology), Luxna Biotech, Ioana Panait, Senior Researcher, Beacon Research Operations, Hanson Wade, Jimmy Weterings, Vice President, Head of Oligonucleotide Therapeutics, Bonito Biosciences, Julie Garlick, Principal Scientist, Genentech, Kathrin Meyer, Chief Scientific Officer and Head of R and D, Alcyone Therapeutics, Meena, Senior Vice President, Translational DMPK and Clinical Pharmacology, Stoke Therapeutics, Muthiah (Mano) Manoharan, Senior Vice President, Innovation Chemistry and Alnylam Distinguished Scientist, Alnylam Pharmaceuticals, Naim Nazef, Vice President - Oligonucleotide Chemistry, Denali Therapeutics Inc., Nicole Lykens, Director of Neurobiology, Global Nucleic Acid Therapies (GNAT), Novo Nordisk, Paul Nioi,, Senior Vice President, Research, Alnylam Pharmaceuticals, Puneet Anand, Senior Principal Scientist, Regeneron, Ron Wange, Associate Director of Pharmacology and Toxicology, USA FDA (formerly), Scott V. Dindot, Executive Director of Molecular Genetics, Ultragenyx Pharmaceuticals, Stefano Zanotti, Vice President and Head of Neuromuscular Research, Dyne Therapeutics